It is also possible that, because CCL5 is sufficient but not necessary for tumor recurrence, it would be preferable to block the induction of the pro-inflammatory program that is induced following Her2 downregulation using agents targeting TNFα or the NFκB pathway. The gene discussed is ERBB2; the disease is neoplasm.